| Document |
Document Title |
|
WO/2023/086098A9 |
Disclosed are ocular sealant formulations and systems for treating ocular wounds. The ocular sealant formulations are administered to a subject by applying the sealant to a surface of the subject's eye. Also disclosed are methods of prep...
|
|
WO/2024/032589A1 |
Provided are a TGF-β inhibitor compound and use thereof. In particular, provided is a compound represented by formula (I) or formula (II) or an isotopically labeled compound, an optical isomer, a geometric isomer, a tautomer, an isomer ...
|
|
WO/2024/034627A1 |
A novel drug for treating or preventing skin hardening in systemic scleroderma has been discovered due to the discovery that skin hardening in systemic scleroderma can be ameliorated by the administration of a sirolimus-containing topica...
|
|
WO/2024/034866A1 |
The present invention pertains to a cosmetic composition. A cosmetic composition according to an aspect increases the expression of VEGF and FGF7 in human follicular dermal papilla cells (HFDPCs), and thus can promote the delivery of nut...
|
|
WO/2024/033418A1 |
The present invention relates to a compound of formula (I), pharmaceutically acceptable salts thereof as well as pharmaceutical compositions comprising the same and, in particular, the compounds of formula (I) and pharmaceutical composit...
|
|
WO/2024/033100A1 |
The present invention belongs to the field of nanoporous materials, in particular metal organic frameworks (MOFs) and Lewis-based gas delivery and/or slow release, or the detection of Lewis-based gas(es) in gases or liquid streams. The p...
|
|
WO/2024/033928A1 |
Method of increasing collagen production and tissue regeneration or repair using an agent that increases an amount of Hypoxia- inducible factor- 1 (HIF-1) in the cells, the amount being selected to cause an increase in the amount of coll...
|
|
WO/2024/032974A1 |
The present invention relates to use of specific group of fatty acids and compositions comprising them for delivering microbiome benefit to skin. This benefit ensures that the skin is protected against undesirable bacteria. The present i...
|
|
WO/2024/033784A1 |
The invention relates to the cosmetic field and more particularly to an oily extract of Moringa peregrina seeds as active ingredient for improving capillary density. The invention also relates to a method for preparing said composition a...
|
|
WO/2024/035864A1 |
The present disclosure relates to therapeutic agents and combinations thereof (e.g., pharmaceutical compositions) for the treatment of inflammation and an inflammatory disease or disorder in a subject, tissue or cell.
|
|
WO/2024/031997A1 |
The present invention relates to N-N-bis-oxazolidinone alkaloid compounds, a preparation method and a use in the medical field. The present invention provides two new N-N-bis-oxazolidinone alkaloid isomers isolated and purified from Loni...
|
|
WO/2024/028448A1 |
The present invention relates to the use of agents able to neutralize the activity of interleukin-15 in the treatment of atopic dermatitis. In particular, the invention relates to IL-15 inhibitors for use in the prevention and/or treatme...
|
|
WO/2024/028796A1 |
The object of the present invention is Udonitrectag (or Negermin or MTS, IUPAC name (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.
1]octane-7- carboxylic acid lysine salt) and pharmaceutical formulation thereof for topical ...
|
|
WO/2024/030600A1 |
The present application provides methods of treating urticaria in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1, or a pharmaceutically acceptable s...
|
|
WO/2024/028519A1 |
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, X, Y and A are as defined herein. These compounds are photodynamic agents that generates reactive oxygen species when subjected to UV radiation. The invention also...
|
|
WO/2024/028863A1 |
The present invention is directed to a pharmaceutical topical composition comprising a Tryptophol derivative and a 4-Ethyl-Phenol derivative. Further provided are methods for using the composition.
|
|
WO/2024/028417A1 |
The present invention concerns a composition comprising at least one mite peptidase 1 or Matrix metallopeptidase 9 (MMP-9) antagonist, and optionally a pharmaceutically acceptable carrier, for use for preventing and/or treating vitiligo ...
|
|
WO/2024/029528A1 |
Antibody preparations for treating allergic diseases have been proposed. However, the route of administration of the antibody preparations is limited to an intravenous route, which imposes a burden on patients. Furthermore, novel drugs t...
|
|
WO/2024/028912A1 |
The present invention concerns gamma-secretase inhibitors for use in the treatment of inherited epidermolysis bullosa and/or fibrosis associated to inherited epidermolysis bullosa, in particular for use in the treatment of recessive dyst...
|
|
WO/2024/029583A1 |
The present invention relates to: a compound represented by formula (I) (wherein Ar1 and Ar2 may be the same as or different from each other, and each represent a substituted or unsubstituted aromatic group; L1 represents a direct bond o...
|
|
WO/2024/028558A1 |
The subject of the present invention is that of preparing glucosylated mycosporines by means of an enzymatic cascade method using α-transglucosylases and sucrose, and use thereof in particular for their anti-UV properties.
|
|
WO/2024/028834A1 |
Cosmetic use of a composition for reducing and/or ameliorating signs of skin aging in an individual, wherein the composition comprises a compound of formula I, wherein the carbon-carbon bond noted Formula II is a double or a single bond,...
|
|
WO/2024/029993A1 |
The present invention relates to a hydrogel patch for wound healing promotion or scar minimization. The use of the hydrogel patch composed of a biocompatible polymer modified with pyrogallol and containing a drug mixture in which PTD-DMB...
|
|
WO/2024/027786A1 |
The present invention provides a Cutibacterium acnes AD3 strain, GDMCC No: 62625. The strain features high propionic acid yields, and can be used for preparing a product for treating an inflammation-related skin disease and improving ski...
|
|
WO/2024/027816A1 |
Provided is a rifamycin-quinolizinone coupled molecule ointment. Raw material components of the rifamycin-quinolizinone coupled molecule ointment comprise, based on the total mass percentage of 100%, rifamycin-quinolizinone coupled molec...
|
|
WO/2024/029639A1 |
The present disclosure relates to a novel compound that allows for the production of monomethyl fumarate after being administered, a pharmaceutical composition containing same as an active ingredient, and a medicinal use thereof.
|
|
WO/2024/028753A1 |
Association comprising or consisting of a dry extract of Polypodium Leucotomos and a dry extract of Larix decidua bark for use in the prevention of damage from exposure to UVA, UVB, UVC and/or IR rays and relative oral nutraceutical or p...
|
|
WO/2024/027807A1 |
Provided is use of an aminothiazole derivative in preparing a drug for immunological inflammation. The aminothiazole derivative has a significant effect on superficial immunological inflammation dermatitis and immunological superficial i...
|
|
WO/2024/029599A1 |
Provided is a pharmaceutical composition containing, as an active ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methox
yphenyl)pyrrolidine-3-yl]carbonyl}-4-(methoxymethyl)pyrrolid
ine-3-yl]-5-(trifluoromethyl)phenyl}p...
|
|
WO/2024/022318A1 |
The present application provides a collagen generation promoter comprising ergothioneine as an effective component, use of ergothioneine in promoting type III collagen generation, and use of ergothioneine in preparing a product for comba...
|
|
WO/2024/023359A1 |
The present invention provides IP4-4,6 substituted derivatives for use in the prevention, inhibition of progression, and treatment of (a) ectopic calcification and the consequences thereof, and (b) a disease and/or condition related to e...
|
|
WO/2024/024520A1 |
Provided is a composition for an external preparation, the composition comprising the below-mentioned components (A) to (D), in which the component (B) comprises at least two components selected from the group consisting of (B1) a cellul...
|
|
WO/2024/021544A1 |
The present invention provides use of vitamin C lactate and analogs thereof in the preparation of articles of manufacture for skin tissue, and related articles of manufacture thereof. The vitamin C lactate and the analogs thereof of the ...
|
|
WO/2024/024565A1 |
The present invention addresses the problem of providing an agent that suppresses cell aging and a drug that prevents or treats diseases and the like caused by cell aging. More specifically, the present invention is a cell aging suppress...
|
|
WO/2024/023715A1 |
The present invention relates to a topical composition comprising a cannabinoid, extracellular matrix component or extracellular matrix fragment, such as an extracellular polysaccharide that is hyaluronic acid, and a pharmaceutically acc...
|
|
WO/2024/023440A1 |
The present invention relates to the novel cosmetic use of a Gentiana crassicaulis extract and/or of a composition comprising same for the cosmetic treatment and/or cosmetic care of healthy skin and/or mucosae selected from skin and/or m...
|
|
WO/2024/026365A1 |
Described herein are topical cream formulations that include a C7–20 alkane, a metal chelating agent, and a buffer.
|
|
WO/2024/024765A1 |
The purpose of the present invention is to provide a multilayer object which has excellent handleability during application to adherends and excellent durability in a dry state and in which the outermost layers on both sides do not diffe...
|
|
WO/2023/220748A9 |
Endoscopic surgery targeted at the sinuses and nasal turbinates assists in managing the symptoms of chronic rhinosinusitis and other conditions. With contemporary techniques, post-operative hemorrhage, synechiae formation and poor wound ...
|
|
WO/2024/023727A1 |
A compound having the structures: Formulae (Ia) or (Ib) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein; R selected from the group cons...
|
|
WO/2024/024915A1 |
Provided is a technique for preventing or treating a periostin-mediated disease and pruritus associated with the disease. The present invention relates to, for example, a prophylactic or therapeutic agent for a periostin-mediated disease...
|
|
WO/2024/023192A1 |
The present invention generally relates to the field of skin care. More particularly, the invention relates to a cosmetic or therapeutic skin care composition comprising at least one skin-health promoting Staphylococcus strain that exert...
|
|
WO/2024/021143A1 |
Disclosed is use of levocetirizine or a pharmaceutically acceptable salt thereof in preparing a medicament for promoting hair growth. The present invention relates to the field of biopharmaceuticals. Research has found that levocetirizin...
|
|
WO/2023/234788A9 |
The present invention relates to a method for the treatment of wounds and/or infections associated with diabetes mellitus or hypoxia, diabetic foot ulcers and/or gangrene, as well as any wound caused by pathogenic microorganisms, said me...
|
|
WO/2024/023190A1 |
The present invention generally relates to the field of skin care. More particularly, the invention relates to a cosmetic or therapeutic skin care composition comprising at least one of the skin-health promoting Staphylococcus strains se...
|
|
WO/2024/022890A1 |
The invention relates to a muscle membrane intended to be affixed to a muscle of a human or animal body, the membrane being capable of at least partially surrounding the muscle, the muscle comprising fibres covered with an outer tissue, ...
|
|
WO/2024/019596A1 |
The present invention relates to a sustained-release formulation containing a 5-alpha-reductase inhibitor, and can be used for the prevention, amelioration, or treatment of prostatic hyperplasia and alopecia.
|
|
WO/2024/020598A1 |
Provided herein are methods of treating nalbuphine-treatable disorders in an elderly patient.
|
|
WO/2024/017880A1 |
A series of substituted imidazo[l,2-b][l,2,4]triazine derivatives of Formula (I) as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments,...
|
|
WO/2024/017331A1 |
The present invention belongs to the fields of bioengineering and biological treatment. Disclosed are an anti-ADM monoclonal antibody or a fragment thereof and a pharmaceutical composition, a detection reagent, or a kit comprising the mo...
|
